About Lymphoma | Advocacy | Art | CAM | Clinical trials | Doctors - Experts - Centers | Guidelines at Diagnosis | News
Risk Factors | Side Effects | Statistics | Support | Symptoms | Tests | Treatments | Types of Lymphoma

Search Site   |  How to Help!

Patients Against Lymphoma

 

Treatmentsabout therapy-related risks

Last update: 02/11/2014

TOPICS
Putting Risks in Perspective | Resources - General | Stem CellTreatment-Related Mortality | Cardiac Toxicity | Immune Suppression | Myelodysplasia & AML- LeukemiaSecondary Cancers ... Melanomas  | Transformation

TOPIC SEARCH: PubMed: Doxorubicin AND cardiac toxicityPurine analogs  AND immune suppression | Auto SCT and secondary cancers

Also see Side Effects | About Transformation

Here we will post abstracts and resources that describe some of the more serious risks associated with cancer therapies, primarily: secondary cancers, myelodysplastic syndrome, and long-term immune suppression. 

But we will also try to put the risks into perspective by noting how likely they are to manifest, and in how much time; and by balancing the risks of treatment against the dangers of delaying or avoiding appropriate treatments.  

For example, while it's true that alkylating agents (such as Leukeran and Cyclophosphamide) increase the risk of developing secondary cancers, the increased risks appear to be relatively small and minimal compared to letting the disease progress unchecked. Importantly the risks can often take many years to emerge, often as long as 10 to 20 years. 

See Related PubMed abstracts & Abstracts on Second Malignancies - Medscape free login req.

Alkylating agents, radiotherapy, autologous transplants, and splenectomy increase the risk of developing MDS (Myelodysplastic Syndrome - failure of the bone marrow to produce healthy and sufficient blood cells), but the risks of developing MDS range from small to significant ( 3 - 12%) depending on the therapy type (Auto Transplant seems to have the highest risk), but this approach is generally tried when the patient has aggressive and/or refractory disease.  

Some treatments may be associated with the transformation of indolent lymphomas to a more aggressive disease. However, be aware that associations between specific treatment and transformation do not prove that one caused the other, because transformation is also a part of the natural course of the disease.  

See About Transformation

It appears to be especially prudent to carefully assess treatment-related risks when the treatment path is unclear, as is often the case for indolent lymphomas.


Resources - General

bullet
Defining and Assessing Quality Cancer Care, - www.nap.edu - PDF 
bullet
Evaluating medical claims and data  

for additional information about the limitations of information provided in 
abstracts and various types of studies.

Collecting Stem Cells following treatment

 
  • MCP Chemotherapy Regimen May Reduce Amount of Stem Cells Collected in Follicular Lymphoma - cancerconsultants.com 

    "According to results recently published in Annals of Oncology, the chemotherapy regimen consisting of melphalan, chlorambucil, and prednisone (MCP) appears to interfere with the ability to collect enough stem cells for an autologous stem cell transplant in patients with follicular non-Hodgkin’s lymphoma.

Treatment-related Mortality

  • Treatment related mortality: Cytochrome P450 2C19 loss-of-function polymorphism is associated with an increased treatment-related mortality in patients undergoing allogeneic transplantation. Bone Marrow Transplant. 2007 Oct;40(7):659-64. Epub 2007 Aug 6. PMID: 17680025 

    Comment: Probably this finding needs to be validated (reproduced by an independent group) before being declared as true, but it shows how normal variations in patients (a polymorphism) can affect outcomes.  In this case, treatment-related mortality is strongly correlated with a specific normal genetic variation 

Cardiac Toxicity

 

Immune suppression - Infectious Complications

Almost all treatments for lymphomas suppress or impair immunity. The degree of immune suppression depends on many factors, including dose, dose timing, and the type of agent.  Some agents are associated with more significant immune suppression than others. In general, younger patients are better able to recover bone marrow function following treatment than the elderly.  

"Fludarabine use in previously treated patients with CLL may be associated with infections involving T-cell dysfunction, such as listeriosis, pneumocystosis, mycobacterial infections, and opportunistic fungal and viral infections. These infections may result from T-cell depletion secondary to fludarabine use. Prophylaxis or presumptive therapy should be initiated when appropriate.

Treatment with alemtuzumab, a monoclonal antibody, affects both B cells and T cells and shows a pattern of infections similar to that of purine analogs. Varicella zoster virus, herpes simplex virus, and CMV are all common in patients with CLL." Source: medscape.com (free login req.)

Related Articles:

bullet
A new model for predicting infectious complications during fludarabine-based combination chemotherapy among patients with indolent lymphoid malignancies. Cancer. 2004 Nov 1;101(9):2042-9. PMID: 15372472
bullet
Warning label added to Rituxan -

the label was "revised to indicate that hepatitis B virus reactivation with fulminant hepatitis, hepatic failure and death has been reported in some patients with hematologic malignancies who were treated with Rituxan since its approval."  - pharmexec.com Oct 2004
bullet
Rituximab treatment results in impaired secondary humoral immune responsiveness.
Blood. 2002 Sep 15;100(6):2257-9. PMID: 12200395 | Related articles
bullet
Infectious complications associated with purine analogs (such as fludarabine) - Related abstracts
bullet
Impact of therapy With chlorambucil, fludarabine, or fludarabine plus chlorambucil on infections in patients with chronic lymphocytic leukemia: Intergroup Study Cancer and Leukemia Group B 9011.
J Clin Oncol. 2001 Aug 15;19(16):3611-21. PMID: 11504743 - PubMed

Myelodysplasia (MDS) & Leukemias

Also See Side Effects > Myelodysplastic Syndrome 

A "rare and potentially fatal blood disorders that occur when the body starts incorrectly manufacturing the three types of blood cells - white, red, and platelets - resulting in malformed, immature cells."  See - Myelodysplasia Syndromes, Basic Explanations  PDF 

The following "Published data suggest that the risk of treatment-related-AML/ and treatment-related MDS following standard chemotherapy is 1% to 1.5% per year from 2-10 years after initiation of therapy.

Leukemogenic therapies are agents that increase the risk of developing leukemias. -  "The risk of leukemia was greatest four or five years after chemotherapy began, and the risk was elevated for at least eight years after the cessation of chemotherapy. The drugs cyclophosphamide, chlorambucil, melphalan, thiotepa, and treosulfan were independently associated with significantly increased risks of leukemia, as was the combination of doxorubicin hydrochloride and cisplatin. Chlorambucil and melphalan were the most leukemogenic drugs, followed by thiotepa; cyclophosphamide and treosulfan were the weakest leukemogens, and the effect per gram was substantially lower at high doses than at lower doses. The extent to which the relative risks of leukemia are offset by differences in chemotherapeutic effectiveness is not known." nejm.org  

bullet
NEW Secondary malignancies after therapy of indolent NHL 
Haematologica 2008 93: 336-338., Jonathan W. Friedberg - full text haematologica.org 

Second malignancies have clearly evolved to be important causes of morbidity and mortality in patients with indolent lymphomas. As survival times increase, and the cohort of patients treated with modalities such as purine analogs, aggressive autologous transplantation and novel radioimmunotherapy grows, it can be expected that the incidence of second cancers will increase significantly. Perhaps most concerning is the lack of an apparent plateau in the incidence curve, even 20–30 years after diagnosis of lymphoma. For this reason, it is critical that patients in prolonged remission remain under care of medical and radiation oncologists attuned to these risks, and undergo at least annual evaluation (history and physical examinations), with appropriate screening tests for second cancers. In the future, emphasis must continue to be given to minimizing toxic therapy to prevent this devastating cost of cure.26 Finally, it is important to realize that the risk of MDS/AML associated with radioimmunotherapy may not be substantially different from the risk in patients treated with standard chemotherapy, including both alkylating agents and purine analogs.
bullet
RIT and risk of MDS: Treatment-related myelodysplastic syndrome (MDS) and AML in patients treated with Zevalin radioimmunotherapy. J Clin Oncol. 2007 Sep 20;25(27):4285-92. Epub 2007 Aug 20.
PMID: 17709799 

Analysis of data from patients ... (746 patients) ... incidences of t-MDS and t-AML (0.7% per year after treatment) are consistent with that expected in patients with NHL who have had extensive previous chemotherapy treatment and do not appear to be increased after treatment with the ibritumomab tiuxetan regimen.
bullet
Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha - bloodjournal.org full 
bullet
Specific Regimen [FND] Influences Risk of Myelodysplasia After Lymphoma Treatment - Medscape (free login req.) or ASCO
bullet
Armitage JO, Carbone PP, Connors JM, et al. Treatment-related myelodysplasia and 
acute leukemia in non-Hodgkin's lymphoma patients. J Clin Oncol. 2003;21:897-906. Abstract
bullet
Secondary myelodysplasia following purine analog therapy - Abstract No: 2477 
bullet
Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011. J Clin Oncol. 2002 Sep 15;20(18):3878-84. PMID: 12228208 - PubMed
bullet
Treatment-Related Myelodysplasia and Acute Leukemia in Non-Hodgkin's Lymphoma Patients. J Clin Oncol. 2003 Mar 1;21(5):897-906. PMID: 12610191 - PubMed | Full text


Secondary Cancers in Lymphoma Survivors

TOPIC SEARCH: PubMed 

bullet
*  JCO, 2010:
Second Malignant Neoplasms in Survivors of Pediatric Hodgkin's Lymphoma Treated With Low-Dose Radiation and Chemotherapy http://bit.ly/1m33v6f

Cumulative incidence of first second malignant neoplasms (SMN) was 17% (95% CI, 10.5 to 26.7) at 20 years after HL diagnosis. The standard incidence ratio (SIR*) for any second malignancy was 22.9 (95% CI, 14.2 to 35) with an absolute excess risk of 93.7 cases per 10,000 person-years.

Standard Incidence ratio (
SIR): "The expected number is calculated by multiplying each age-specific cancer incidence rate of the reference population by each age-specific population of the community in question and then adding up the results. If the observed number of cancer cases equals the expected number, the SIR is 1. If more cases are observed than expected, the SIR is greater than 1. If fewer cases are observed than expected, the SIR is less than 1.  www.state.nj.us
bullet
Secondary malignancies after therapy of indolent non-Hodgkin’s lymphoma

Jonathan W. Friedberg haematologica.org/

The true incidence of MDS/AML and other secondary malignancies after treatment for indolent lymphoma, outside of the setting of autologous transplantation, is largely unknown. Historical series have suggested that the incidence of secondary malignancies is almost double the expected incidence over a 10-year follow-up period and patients treated with total body irradiation have an even higher risk.13–15
bullet
Secondary Malignancies: What, When, Why, in Whom? - Smita Bhatia, MD, MPH 

NCCN Clinical Practice Oncology Forum. 2008; ©2008 NCCN Clinical Practice Oncology Forum
Posted 10/27/2008

The growing population of cancer survivors carries a significant burden of morbidity, necessitating comprehensive long-term follow-up, which should ideally begin at the completion of active therapy. 

Documentation of therapeutic exposures will form the basis for use of recommendations within the long-term follow-up guidelines, thus ensuring standardization of care received by the survivors. However, many barriers prevent effective follow-up, the most fundamental of which are the lack of understanding by long-term survivors about their risk, as well as by the primary care physicians caring for them. 

Shortcomings of the healthcare system are also potential barriers to long-term follow-up, and include infrastructure issues, such as a lack of capacity within centers, training and educational deficiencies, and inadequate/ineffective communication between oncologists and primary care physicians who subsequently provide the large bulk of follow-up care.
bullet
Risk factors for development of a second lymphoid malignancy in patients with CLL. 
Br J Haematol. 2007 Nov;139(3):398-404. PMID: 17910629
bullet
The risk of secondary malignancies over 30 years after the treatment of non-Hodgkin lymphoma.
Cancer. 2006 May 17;  PMID: 16708354 | Related articles
bullet
Cancer risk higher in lymphoma survivors - reuters.com 

"Survivors had an 8.8-fold increased risk of leukemia and a 1.6-fold risk of lung cancer, according to the report in the Journal of Clinical Oncology"
bullet
Risk of Second Malignancy After Non-Hodgkin's Lymphoma: A British Cohort Study.
J Clin Oncol. 2006 Mar 6; [Epub ahead of print] PMID: 16520465 | Related articles
bullet
Researchers Learn More About Secondary Cancers After Non-Hodgkin's Lymphoma - cancerconsultants.com 
bullet
Second cancers among long-term survivors of non-Hodgkin's lymphoma.
J Natl Cancer Inst. 1993 Dec 1;85(23):1932-7. PMID: 8230284 
bullet
Risk of leukemia following treatment for non-Hodgkin's lymphoma - jncicancerspectrum.oxfordjournals.org/

"Our results suggest that prednimustine may be a human carcinogen, with a positive dose-response gradient evident for ANLL risk. The low, nonsignificant risk of leukemia associated with cyclophosphamide was reassuring because this drug is commonly used today. Despite the excesses of ANLL associated with specific therapies, secondary leukemia remains a rare occurrence following NHL. Of 10,000 NHL patients treated for 6 months with selected regimens including low cumulative doses of cyclophosphamide and followed for 10 years, an excess of four leukemias might be expected."
bullet
AAOS: Increased Rate of Secondary Cancers Seen in Long-Term Osteosarcoma Survivors - pslgroup.com
bullet
MEDLINE Abstracts: Second Malignancies from Medscape Hematology-Oncology 
What's new about therapy-related malignancies in cancer patients? - Medscape free login req.
bullet
New malignancies after blood or marrow stem-cell transplantation in children and adults: incidence and risk factors. J Clin Oncol. 2003 Apr 1;21(7):1352-8. Erratum in: J Clin Oncol. 2003 Aug 15;21(16):3181.
PMID: 12663726 | Abstracts
bullet
Researchers Learn More About Secondary Cancers After Non-Hodgkin’s Lymphoma - cancerconsultants.com  
 
" Researchers concluded that secondary cancers after NHL are often treatment-related, but other sources, such as immune suppression and environmental exposures, may also play a role in the development of secondary cancers and malignancies."
bullet
Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma - bloodjournal.org


Melanomas

It is prudent to check for melanoma often if you have lymphoma.

If you have any of the above features - or anything else out of the ordinary - show your doctor as soon as possible. 

Source: RITE AID pharmacy

 


Transformation

See About transformation

bullet
Fludarabine and Transformation? ~ a scientist with NHL reviews the papers.
bullet
Large-cell transformation of chronic lymphocytic leukemia and follicular lymphoma during or soon after treatment with fludarabine-rituximab-containing regimens: natural history- or therapy-related complication? Eur J Haematol. 2002 Feb;68(2):80-3. PMID: 12038452 - PubMed
 
Disclaimer:  The information on Lymphomation.org is not intended to be a substitute for 
professional medical advice or to replace your relationship with a physician.
For all medical concerns,  you should always consult your doctor. 
Patients Against Lymphoma, Copyright © 2004,  All Rights Reserved.